The state of norovirus vaccines

Clinical Infectious Diseases

Volumn 58, Issue 12, 2014, Pages 1746-1752

  Debbink, Kari ^a   Lindesmith, Lisa C ^b   Baric, Ralph S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

Author keywords

norovirus; vaccine

Indexed keywords

NOROVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

ANTIGENICITY; ARTICLE; DISEASE COURSE; DISEASE TRANSMISSION; DRUG DESIGN; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; NOROVIRUS; PRIORITY JOURNAL; VACCINATION; VIRUS CAPSID; VULNERABLE POPULATION; CALICIVIRIDAE INFECTIONS; DRUG DEVELOPMENT; IMMUNOLOGY;

CALICIVIRIDAE INFECTIONS; DRUG DISCOVERY; HUMANS; NOROVIRUS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES; VULNERABLE POPULATIONS;

EID: 84901770358     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu120     Document Type: Article

References (42)

1. Hall AJ, Lopman BA, Payne DC, et al. Norovirus disease in the United States. Emerg Infect Dis 2013; 19:1198-205.
2. Mattner F, Sohr D, Heim A, Gastmeier P, Vennema H, Koopmans M. Risk groups for clinical complications of norovirus infections: an outbreak investigation. Clin Microbiol Infect 2006; 12:69-74.
3. Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY. The potential economic value of a human norovirus vaccine for the United States. Vaccine 2012; 30:7097-104.
4. Kroneman A, Vega E, Vennema H, et al. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 2013; 158: 2059-68.
5. Vega E, Barclay L, Gregoricus N, Shirley SH, Lee D, Vinje J. Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009-2013. J Clin Microbiol 2013; 52:147-55.
6. Teunis PF, Moe CL, Liu P, et al. Norwalk virus: how infectious is it? J Med Virol 2008; 80:1468-76.
7. Atmar RL, Opekun AR, Gilger MA, et al. Determination of the human infectious dose-50% for Norwalk virus. J Infect Dis 2013.
8. Taube S, Kolawole AO, Hohne M, et al. A mouse model for human norovirus. MBio 2013; 4:4 e00450-13.
9. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol 2002; 76:12335-43.
10. Reeck A, Kavanagh O, Estes MK, et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010; 202:1212-8.
11. Souza M, Costantini V, Azevedo MS, Saif LJ. A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine 2007; 25:8448-59.
12. Bok K, Parra GI, Mitra T, et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci USA 2011; 108:325-30.
13. LoBue AD, Lindesmith L, Yount B, et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 2006; 24:5220-34.
14. Lindesmith LC, Donaldson EF, LoBue AD, et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 2008; 5:e31.
15. Lindesmith LC, Debbink K, Swanstrom J, et al. Monoclonal antibodybased antigenic mapping of norovirus GII.4-2002. J Virol 2012; 86:873-83.
16. Debbink K, Donaldson EF, Lindesmith LC, Baric RS. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol 2012; 86:1214-26.
17. Allen DJ, Noad R, Samuel D, Gray JJ, Roy P, Iturriza-Gomara M. Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding. Virol J 2009; 6:150.
18. Lindesmith LC, Donaldson EF, Baric RS. Norovirus GII.4 strain antigenic variation. J Virol 2011; 85:231-42.
19. Lindesmith LC, Costantini V, Swanstrom J, et al. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol 2013; 87:2803-13.
20. Debbink K, Lindesmith LC, Donaldson EF, et al. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis 2013; 208:1877-87.
21. Boon D, Mahar JE, Abente EJ, et al. Comparative evolution of GII.3 and GII.4 norovirus over a 31-year period. J Virol 2011; 85:8656-66.
22. Swanstrom J, Lindesmith LC, Donaldson EF, Yount B, Baric RS. Characterization of blockade antibody responses in GII.2.1976 SMV infected subjects. J Virol 2013; 88:829-37.
23. Simmons K, Gambhir M, Leon J, Lopman B. Duration of immunity to norovirus gastroenteritis. Emerg Infect Dis 2013; 19:1260-7.
24. Tobin GJ, Trujillo JD, Bushnell RV, et al. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 2008; 26:6189-99.
25. Parra GI, Bok K, Taylor R, et al. Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 2012; 30:3580-6.
26. Pomfret TC, Gagnon JM Jr., Gilchrist AT. Quadrivalent human papillomavirus (HPV) vaccine: A review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther 2011; 36:1-9.
27. El-Kamary SS, Pasetti MF, Mendelman PM, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibodysecreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010; 202:1649-58.
28. Ramirez K,Wahid R, Richardson C, et al. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin Immunol 2012; 144:98-108.
29. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 2011; 365: 2178-87.
30. Takeda Highlights Data from Clinical Trial of Investigational Norovirus Vaccine Candidate. 2013. https://www.takeda.com/news/2013/20131007-6021.html. Accessed 10 March 2014.
31. Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One 2013; 8:e70409.
32. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000; 182:302-5.
33. Fang H, TanM, Xia M,Wang L, Jiang X. Norovirus P particle efficiently elicits innate, humoral and cellular immunity. PLoS One 2013; 8: e63269.
34. Wang L, Huang P, Fang H, et al. Polyvalent complexes for vaccine development. Biomaterials 2013; 34:4480-92.
35. Tamminen K, Huhti L, Koho T, et al. A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology 2012; 135:89-99.
36. Lindesmith LC, Beltramello M, Donaldson EF, et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 2012; 8:e1002705.
37. Koo HL, DuPont HL. Noroviruses as a potential cause of protracted and lethal disease in immunocompromised patients. Clin Infect Dis 2009; 49:1069-71.
38. Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med 2012; 367:2126-32.
39. Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman RSztein MB. Vaccination in the elderly: an immunological perspective. Trends Immunol 2009; 30:351-9.
40. Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solidorgan transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003; 16:357-64.
41. Delacour H, Dubrous P, Koeck JL. Noroviruses: A challenge for military forces. J R Army Med Corps 2010; 156:251-4.
42. Hall AJ, Eisenbart VG, Etingue AL, Gould LH, Lopman BA, Parashar UD. Epidemiology of foodborne norovirus outbreaks, United States, 2001-2008. Emerg Infect Dis 2012; 18:1566-73.